(Q37035281)

17 August 2017

1 reference

title

Stat5 as a diagnostic marker for leukemia (English)

1 reference

17 August 2017

0 references

1 reference

Rowena S Lewis

1

1 reference

17 August 2017

Alister C Ward

series ordinal

2

1 reference

17 August 2017

publication date

1 January 2008

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

73-82

1 reference

Activation of STAT proteins and growth control

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

SOCS proteins: negative regulators of cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Signaling through the JAK/STAT pathway, recent advances and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Signaling of type II oncostatin M receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Characterization of the signaling capacities of the novel gp130-like cytokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The role of STATs in transcriptional control and their impact on cellular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Anti-apoptotic role of STAT5 in haematopoietic cells and in the pathogenesis of malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Stat5a is mandatory for adult mammary gland development and lactogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA binding protein. Proposed role as an intracellular regulator of male-specific liver gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Stat5a/b are essential for normal lymphoid development and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Signal transducer and activator of transcription proteins in leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

STAT5 signaling is required for the efficient induction and maintenance of CML in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Janus kinase 2: a critical target in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The Stat5-RARalpha fusion protein represses transcription and differentiation through interaction with a corepressor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Polycythemia vera: myths, mechanisms, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

PRV-1 mRNA expression discriminates two types of essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Regulation of the Jak2 tyrosine kinase by its pseudokinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Constitutive activation of zebrafish Stat5 expands hematopoietic cell populations in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Identification of a high-affinity phosphopeptide inhibitor of Stat3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Targeting Stat3 in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

Stat5 tetramer formation is associated with leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.1.73

21 January 2018

Identifiers

DOI

10.1586/14737159.8.1.73

1 reference

17 August 2017

1 reference